Lipoprotein-associated phospholipase A2 and risk of dementia in the Cardiovascular Health Study

被引:43
作者
Fitzpatrick, Annette L. [1 ,2 ]
Irizarry, Michael C. [3 ,4 ]
Cushman, Mary [5 ,6 ]
Jenny, Nancy S. [6 ]
Chi, Gloria C. [1 ]
Koro, Carol [3 ,4 ]
机构
[1] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA
[2] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA
[3] GlaxoSmithKline, WW Epidemiol, Res Triangle Pk, NC USA
[4] GlaxoSmithKline, WW Epidemiol, Upper Merion, PA USA
[5] Univ Vermont, Coll Med, Dept Med, Burlington, VT 05405 USA
[6] Univ Vermont, Coll Med, Dept Pathol, Burlington, VT 05405 USA
关键词
Lp-PLA(2); Dementia; Alzheimer's disease; Cardiovascular risk factors; ACTIVATING-FACTOR ACETYLHYDROLASE; CORONARY-HEART-DISEASE; ALZHEIMERS-DISEASE; OLDER-ADULTS; ATHEROSCLEROSIS; INFLAMMATION; BIOMARKERS; DIAGNOSIS;
D O I
10.1016/j.atherosclerosis.2014.04.032
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To evaluate associations between Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) mass and activity with risk of dementia and its subtypes. Methods: Analysis were completed on 3320 participants of the Cardiovascular Health Study (CHS), a population-based longitudinal study of community-dwelling adults age >= 65 years followed for an average of 5.4 years. Baseline serum Lp-PLA(2) mass was measured using a sandwich enzyme immunoassay and Lp-PLA(2) activity utilized a tritiated-platelet activating factor activity assay. Cox proportional hazards regression assessed the relative risk of incident dementia with higher baseline Lp-PLA(2) adjusting for demographics, cardiovascular disease (CVD) and risk factors, inflammation markers and apolipoprotein E (APOE) genotype. Results: Each standard deviation higher Lp-PLA2 mass and activity were related to increased risk of dementia (fully adjusted HR: 1.11 per SD, 95% CI: 1.00-1.24 for mass; HR: 1.12 per SD, 95% CI: 1.00-1.26 for activity). Persons in the highest quartile of Lp-PLA(2) mass were 50% more likely to develop dementia than those in the lowest quartile in adjusted models (HR: 1.49; 95% CI: 1.08-2.06). Among dementia subtypes, the risk of AD was increased two-fold in the highest compared to lowest quartile of Lp-PLA(2) mass (adjusted HR: 1.98, 95% CI: 1.22-3.21). Results were attenuated in models of mixed dementia and VaD. Lp-PLA(2) activity also doubled the risk of mixed dementia in the highest compared to lowest quartile (HR: 2.21, 95% CI: 1.12-4.373). Interpretation: These data support Lp-PLA(2) as a risk factor for dementia independent of CVD and its risk factors. Further study is required to clarify the role of Lp-PLA(2)-related mechanisms in dementia subtypes. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:384 / 391
页数:8
相关论文
共 39 条
[1]  
Anstey KJ, 2008, AM J GERIATRIC PSYCH, V16
[2]  
APA: DSM-IV, 1994, DSM 4 DIAGN STAT MAN
[3]   Cellular source(s) of platelet-activating-factor acetylhydrolase activity in plasma [J].
Asano, K ;
Okamoto, S ;
Fukunaga, K ;
Shiomi, T ;
Mori, T ;
Iwata, M ;
Ikeda, Y ;
Yamaguchi, K .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1999, 261 (02) :511-514
[4]   Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study [J].
Ballantyne, CM ;
Hoogeveen, RC ;
Bang, H ;
Coresh, J ;
Folsom, AR ;
Heiss, G ;
Sharrett, AR .
CIRCULATION, 2004, 109 (07) :837-842
[5]   Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase:: a potential new risk factor for coronary artery disease [J].
Caslake, MJ ;
Packard, CJ ;
Suckling, KE ;
Holmes, SD ;
Chamberlain, P ;
Macphee, CH .
ATHEROSCLEROSIS, 2000, 150 (02) :413-419
[6]   Lipoprotein-associated phospholipase A2 (platelet-activating factor acetylhydrolase) and cardiovascular disease [J].
Caslake, MJ ;
Packard, CJ .
CURRENT OPINION IN LIPIDOLOGY, 2003, 14 (04) :347-352
[7]   CRITERIA FOR THE DIAGNOSIS OF ISCHEMIC VASCULAR DEMENTIA PROPOSED BY THE STATE OF CALIFORNIA ALZHEIMERS-DISEASE-DIAGNOSTIC-AND-TREATMENT-CENTERS [J].
CHUI, HC ;
VICTOROFF, JI ;
MARGOLIN, D ;
JAGUST, W ;
SHANKLE, R ;
KATZMAN, R .
NEUROLOGY, 1992, 42 (03) :473-480
[8]   Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker [J].
Corson, Marshall A. ;
Jones, Peter H. ;
Davidson, Michael H. .
AMERICAN JOURNAL OF CARDIOLOGY, 2008, 101 (12A) :41F-50F
[9]  
CUSHMAN M, 1995, CLIN CHEM, V41, P264
[10]  
Dadu RT, 2012, TRANSL RES, P1